TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03868735

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CleanSweep Closed Suction System
Description: Device with balloon sweeping technology
Study: NCT00649389

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrochlorothiazide
Description: Hydrochlorothiazide 25mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrochlorothiazide
Description: Hydrochlorothiazide 25mg
Study: NCT00278148

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: AUC2 weekly x 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: AUC2 weekly x 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: Daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: Daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: Daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: 50mg/m2/weekly x 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: 50mg/m2/weekly x 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: 50mg/m2/weekly x 3 weeks

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: conventional surgery
Description: conventional surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: conventional surgery
Description: conventional surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: conventional surgery
Description: conventional surgery

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: 150 cGy bid

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: 150 cGy bid

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: 150 cGy bid
Study: NCT02603068

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral treprostinil
Description: Oral treprostinil will be administered as TID dosing for up to 16 Weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral treprostinil
Description: Oral treprostinil will be administered as TID dosing for up to 16 Weeks.
Study: NCT02634268

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Lifestyle Intervention
Description: Behavioral lifestyle intervention focused on healthy eating and physical activity
Study: NCT03603951

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR2554
Description: SHR2554 is a selective small molecule inhibitor of the histone-lysine methyltransferase EZH2.
Study: NCT00072436

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alvocidib
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study: NCT02813447

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sertraline

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00439348

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Verbal advice
Description: Patients receive verbal advice regarding specific over-the-counter medications.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prescription
Description: Patients receive a prescription for a specific over-the-counter medication.
Study: NCT00672763

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Colecalciferol D3 (Vigantol Oil)
Description: 1. Standard oral Prednisolone 40mg daily (or Budesonide 9mg daily) for 4 weeks;~2. Supplemental calcium and vitamin D3 (CalcichewD3Forte) 1000mg and 800iU respectively daily for duration of steroid treatment;~3. Colecalciferol 100,000iU orally once fortnightly for 4 weeks (2 doses).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Medium chain triglycerides
Description: 1. Standard oral Prednisolone 40mg daily (or Budesonide 9mg daily) for 4 weeks;~2. Supplemental calcium and vitamin D3 (CalcichewD3Forte) 1000mg and 800iU respectively daily for duration of steroid treatment;~3. Migliol Oil 5ml oral fortnightly (2 doses)
Study: NCT00676195

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-Acetyl Cysteine
Description: Dosage of orally administered N-Acetyl Cysteine is as follows:~Days 1-30: 900 mg, once per day Days 31-60: 900 mg, twice per day Days 61-90: 900 mg, three times per day
Study: NCT02548754

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Parasym device

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Parasym device
Study: NCT04656197

Intervention type: OTHER
Intervention: Ocular microbiome
Description: Taxonomical and functional characterization of the ocular microbiome

Intervention type: OTHER
Intervention: Ocular microbiome
Description: Taxonomical and functional characterization of the ocular microbiome
Study: NCT03420807

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MHRC
Description: Evaluate the feasibility of detection of beta-amyloid plaques by using their spectral signature in autofluorescence or reflectance.
Study: NCT01294007

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PureGen Osteoprogenitor Cell Allograft
Description: PureGen Osteoprogenitor Cell Allograft with posterior transpedicular fixation.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Autograft bone
Description: Iliac Crest and Local Autograft Bone
Study: NCT00318851

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Carotid Stent with Distal Protection Device
Description: Carotid Stent Placement with Distal Protection
Study: NCT02686242

Intervention type: PROCEDURE
Intervention: spinal anesthesia
Description: bupivacaine injected by spinal puncture

Intervention type: PROCEDURE
Intervention: general anesthesia
Description: general anesthesia with intubation
Study: NCT00904202

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Capsules + Placebo Patch
Description: Patients participated in a 5-week treatment period. Eligible patients were randomized into one of four treatment groups: placebo capsules + placebo patch (Placebo Group), placebo capsules + Lidoderm patch (Lidocaine Group), Gabapentin capsules 1800 mg/day + placebo patch (Gabapentin Group), or Gabapentin capsules 1800 mg/day + Lidoderm patch (Combination Group).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo capsules + Lidoderm®
Description: Patients participated in a 5-week treatment period. Eligible patients were randomized into one of four treatment groups: placebo capsules + placebo patch (Placebo Group), placebo capsules + Lidoderm patch (Lidocaine Group), Gabapentin capsules 1800 mg/day + placebo patch (Gabapentin Group), or Gabapentin capsules 1800 mg/day + Lidoderm patch (Combination Group).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gabapentin + Placebo
Description: Patients participated in a 5-week treatment period. Eligible patients were randomized into one of four treatment groups: placebo capsules + placebo patch (Placebo Group), placebo capsules + Lidoderm patch (Lidocaine Group), Gabapentin capsules 1800 mg/day + placebo patch (Gabapentin Group), or Gabapentin capsules 1800 mg/day + Lidoderm patch (Combination Group).

Intervention type: DRUG
Group type: OTHER
Intervention: Gabapentin + Lidoderm®
Description: Patients participated in a 5-week treatment period. Eligible patients were randomized into one of four treatment groups: placebo capsules + placebo patch (Placebo Group), placebo capsules + Lidoderm patch (Lidocaine Group), Gabapentin capsules 1800 mg/day + placebo patch (Gabapentin Group), or Gabapentin capsules 1800 mg/day + Lidoderm patch (Combination Group).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gabapentin 300 mg capsules 1800 mg/day + placebo patch
Description: Gabapentin 300 mg capsules 1800 mg/day + placebo patch

Intervention type: DRUG
Group type: OTHER
Intervention: Gabapentin 1800 mg/day + Lidoderm patch
Study: NCT04955665

Intervention type: PROCEDURE
Intervention: bone block procedure
Description: a 20 × 15 × 3 mm3 bone block was cut from the lateral malleolus, rotated backwards 45°, and sutured back to the periosteum of the lateral malleolus using non-absorbable sutures.

Intervention type: PROCEDURE
Intervention: Reattachment of the superior peroneal retinaculum
Description: two suture anchors (Mini Quickanchor,DePuy Mitek) were inserted into the postero-lateral ridge of the lateral malleolus without damaging the cartilaginous ridge, after which the SPR was reattached to the lateral malleolus with the anchored suture. The inner layer of the false pouch was incised, and the outer layer (periosteum) was sutured with the SPR in a pants-over-vest style.
Study: NCT04000698

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Preparative regimen
Description: Preparative chemotherapy before allogeneic HSCT~* Fludarabin~* Cytarabine~* Venetoclax~* Daratumomab~* Vecanoid Condition~* treosulfan~* fludarabine~* thiophosphomide~* Venetoclax~* Plerixafor GVHD prophylaxis~* abatacept~* tocilizumab~* rituximab~* HSCT from the haploidentical donor, ex vivo depleted of alpha/beta T lymphocytes
Study: NCT04612881

Intervention type: DRUG
Intervention: fitostimoline vaginal pessaries
Description: vaginal pessaries

Intervention type: OTHER
Intervention: standard of care
Description: standard of care
Study: NCT02191176

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dextromethorphan syrup - low dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dextromethorphan syrup - high dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01447446

Intervention type: DRUG
Intervention: Peg-IFN Alfa-2a
Description: Peg-IFN Alfa-2a according to standard of care and in line with local labeling.

Intervention type: DRUG
Intervention: Peg-IFN Alfa-2a
Description: Peg-IFN Alfa-2a according to standard of care and in line with local labeling.

Intervention type: DRUG
Intervention: Peg-IFN Alfa-2a
Description: Peg-IFN Alfa-2a according to standard of care and in line with local labeling.

Intervention type: DRUG
Intervention: Peg-IFN Alfa-2b
Description: Peg-IFN Alfa-2b according to standard of care and in line with local labeling.

Intervention type: DRUG
Intervention: Peg-IFN Alfa-2b
Description: Peg-IFN Alfa-2b according to standard of care and in line with local labeling.

Intervention type: DRUG
Intervention: Peg-IFN Alfa-2b
Description: Peg-IFN Alfa-2b according to standard of care and in line with local labeling.

Intervention type: DRUG
Intervention: Ribavirin
Description: Ribavirin according to standard of care and in line with local labeling.

Intervention type: DRUG
Intervention: Ribavirin
Description: Ribavirin according to standard of care and in line with local labeling.

Intervention type: DRUG
Intervention: Ribavirin
Description: Ribavirin according to standard of care and in line with local labeling.

Intervention type: DRUG
Intervention: Ribavirin
Description: Ribavirin according to standard of care and in line with local labeling.

Intervention type: DRUG
Intervention: Ribavirin
Description: Ribavirin according to standard of care and in line with local labeling.

Intervention type: DRUG
Intervention: Ribavirin
Description: Ribavirin according to standard of care and in line with local labeling.

Intervention type: DRUG
Intervention: Boceprevir
Description: Boceprevir according to standard of care and in line with local labeling.

Intervention type: DRUG
Intervention: Boceprevir
Description: Boceprevir according to standard of care and in line with local labeling.

Intervention type: DRUG
Intervention: Telaprevir
Description: Telaprevir according to standard of care and in line with local labeling.

Intervention type: DRUG
Intervention: Telaprevir
Description: Telaprevir according to standard of care and in line with local labeling.
Study: NCT02719912

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: mitral valve replacement
Description: transcatheter mitral valve replacement
Study: NCT02284659

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Functional Electrical Stimulation (FES)
Description: FES (50Hz / 500us)

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: FES- Sham
Study: NCT02925715

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ultrasound guided central venous cannulation
Description: ultrasound is a medical device which is frequently used for safe venous punctures as you can visualise the structures.so, device ''ultrasound'' will be used for intervention ''central line insertion'' in subclavian vein. ultrasound guided cannulation of the subclavian vein was done by supraclavicular or infraclavicular approach after randomization into either of the two groups.In the supraclavicular approach the puncture site is above the clavicle while in the infraclavicular group the puncture site is below the clavicle. Central venous cannulation is done after identifying the vein on ultrasound and using standard seldinger technique with full asepsis.
Study: NCT03149263

Intervention type: BEHAVIORAL
Intervention: distraction
Description: Children will all benefit toxin injections with the same protocol. Only the distraction will be different during the session: either the children will have a distraction realized by the team of clowns / or children will benefit a classic distraction (TV, music, ...)

Intervention type: BEHAVIORAL
Intervention: distraction
Description: Children will all benefit toxin injections with the same protocol. Only the distraction will be different during the session: either the children will have a distraction realized by the team of clowns / or children will benefit a classic distraction (TV, music, ...)
Study: NCT00315913

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propranolol
Description: IV Propranolol 1mg/min for a total of 2 minutes. Total dose 2mg

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: IV Placebo
Description: IV Saline Solution
Study: NCT01382940

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rituximab
Description: 1000 mg in 250 mL intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Description: 10 to 25 mg/week (oral or parenteral)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methylprednisolone
Description: 100 mg methylprednisolone administered by slow intravenous infusion at least 30 minutes prior to the start of each study drug infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: acetaminophen
Description: 1 gram acetaminophen administered orally 30 to 60 minutes prior to the start of each study drug infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: antihistamine
Description: 50 mg diphenhydramine hydrochloride or equivalent dose of alternate antihistamine administered orally 30 to 60 minutes prior to the start of each study drug infusion
Study: NCT01493661

Intervention type: OTHER
Intervention: Chronic Sleep Restriction
Description: All volunteers will undergo 25% of sleep restriction of their total sleep time at the beginning sleep for five consecutive days. The nights will be monitored by polysomnography.

Intervention type: OTHER
Intervention: Chronic Sleep Restriction
Description: All volunteers will undergo 25% of sleep restriction of their total sleep time at the beginning sleep for five consecutive days. The nights will be monitored by polysomnography.

Intervention type: OTHER
Intervention: Chronic Sleep Restriction
Description: All volunteers will undergo 25% of sleep restriction of their total sleep time at the beginning sleep for five consecutive days. The nights will be monitored by polysomnography.
Study: NCT04014478

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endovascular Denervation
Description: A radiofrequency ablation catheter will be placed in abdominal aorta. At least 6 sites will be ablated with settings of temerature at 60 degree centigrade and time at 120 seconds.
Study: NCT00836173

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RICE
Description: RICE treatment: Rituximab by intravenous infusion over 6-8 hours on day 1, Eptoposide by intravenous infusion over 2 hours on day 3-5, a 1-hour infusion of Carboplatin on day 4 and a 24-hour infusion of Ifosfamide on day 4, each cycle is 14 days (2 weeks). Patients will receive 3 cycles of RICE treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GaRD Treatment
Description: After RICE treatment, patients will have gallium nitrate IV through a vein continuously over a 7 day period. Patients will also receive rituximab by intravenous infusion over a 3-6 hour period on day 1 of each cycle. Dexamethasone will be given as pills to be taken for 4 days in a row on the first 4 days of each cycle. The length of each cycle is 21 days (3 weeks). All patients will have 2 cycles of GaRD.
Study: NCT01752595

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Preference Based Rhythmic Auditory Stimulation Music
Description: Patients that have been randomized into arms 2 and 3 will be blinded to the intervention they are receiving (i.e. preference-based playlist vs. preference-based playlist that has been edited to include Rhythmic Auditory Stimulation (RAS). RAS drives synchronous neural oscillation (entrainment) and functions in two ways: (1) facilitates pace and heart-rate synchrony and (2) facilitates brain state dominance (getting into the zone). RAS will be accomplished through: (1) sequencing of subject self-selected music based on tempo, (2) accentuation of the rhythmic driving pulse with added percussive-type sounds, (3) addition of binaurally detuned pitches to follow bass lines at brain-state target frequencies (e.g., 8 Hz alpha, or 16 Hz beta), and (4) the addition of binaurally detuned background sounds (e.g., low frequency hum) at target Hz frequencies. RAS is implemented as inherent and natural to the music and may remain imperceptible to most.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Preference Based Music Intervention
Study: NCT03273140

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Gamification Diabetes Education Program (GDEP)
Description: Diabetic application focuses on diabetes management and consists of two gamelets and consist of story-telling, case scenarios with the integration of problem-based decision-making and solving skills in diabetes management. These scenarios created are familiar to the patients and nurses - to make the games more interactive and realistic to the players (participants). Immediate feedback will be given after they select their decision. The visual reward will appear after attaining one score for each correct question. Participants can easily access and play the games several times till contents are reinforced and knowledge is retained or at their own comfort level. This game mechanics aim to motivate and assist patients to achieve their desired result and self-efficacy behaviors. It addresses the deficits from the current literature review, by aiming to be up-to-date, reliable with new updated scenarios and platform.
Study: NCT00329017

Intervention type: PROCEDURE
Intervention: Fine needle aspiration
Description: Fine needle aspiration
Study: NCT02936492

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY1003803 0.01% lipophilic cream
Description: Topical administration for 22 h per day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY1003803 0.1% lipophilic cream
Description: Topical administration for 22 h per day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY1003803 0.01% ointment
Description: Topical administration for 22 h per day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY1003803 0.1% ointment
Description: Topical administration for 22 h per day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lipophilic cream vehicle
Description: Topical administration for 22 h per day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ointment vehicle
Description: Topical administration for 22 h per day
Study: NCT01097395

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ribavirin
Description: Randomization to standard weight based ribavirin dosing (1000 or 1200 mg daily) or concentration-guided dosing based on first dose AUC0-12

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ribavirin
Description: Randomization to standard weight based ribavirin dosing (1000 or 1200 mg daily) or concentration-guided dosing based on first dose AUC0-12
Study: NCT03621722

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Elequil Aromatabs
Description: There will be a variety of different Aromatabs such as orange/peppermint or lavender

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Elequil Aromatabs
Description: There will be a variety of different Aromatabs such as orange/peppermint or lavender
Study: NCT04896944

Intervention type: OTHER
Intervention: No intervention
Description: No intervention

Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study: NCT02609659

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ombitasvir/paritaprevir/ritonavir and dasabuvir
Description: Tablet; ombitasvir coformulated with paritaprevir and ritonavir, dasabuvir tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ribavirin
Description: Tablet
Study: NCT02936492

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clobetasol propionate
Description: Topical administration for 22 h per day
Study: NCT01176136

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Homework, Organization, and Planning Skills (HOPS) Intervention
Description: HOPS is a 16 session school-based intervention. School counselors and psychologists deliver the intervention during the school day. Each session lasts 20 minutes. Initially, sessions are 2 times per week and the entire HOPS intervention is completed in 11 weeks. The study uses a waitlist control design. HOPS intervention participants (Arm 1) receive the intervention in the fall quarter of the school year and Treatment As Usual participants (Arm 2) receive the intervention in the spring quarter.
Study: NCT00924599

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prevention of recurrent gestational diabetes through weight loss and exercise (English & Spanish)
Description: Intervention groups will attend weekly sessions focused on healthy weight loss, healthy eating, exercise.
Study: NCT02757521

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitrous Oxide
Description: 50% nitrous oxide/ 50% oxygen, 3 one hour inhalation treatments per Stage, every other day (M,W,F)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 50% nitrogen {inert}/ 50% oxygen, 3 one hour inhalation treatments per Stage, every other day (M,W,F)
Study: NCT04258085

Intervention type: OTHER
Intervention: Early diagnosis program combined with electronic medical record
Description: Implementation of early diagnosis approach targeting symptomatic women, combined with use of electronic medical record to facilitate documentation, patient tracking across levels of the health care system, and patient contact